At1g50220 Antibody

2.2. Antibody Nomenclature Pitfalls

• AT1 Receptor Antibodies: Six commercially available AT1 receptor antibodies (e.g., sc-1173, sc-579) were found non-specific in validation studies . These antibodies target the angiotensin II receptor but lack reliable specificity.

• Recombinant Antibody Systems: Modern antibody production methods (e.g., phage display, codon optimization) focus on therapeutic targets like SARS-CoV-2 or cancer . No mention of "At1g50220" in such contexts.

Comparative Analysis of Antibody Specificity and Validation

4.1. Recombinant Antibody Production

• Applications: Used for detecting biomarkers, treating autoimmune diseases, and developing cancer therapies .

• Workflow: Combines gene synthesis, codon optimization, and expression in mammalian systems (e.g., ExpiCHO) .

• Case Study: SARS-CoV-2 antibody ab1 demonstrated pan-neutralizing activity in mice and hamsters, with no aggregation issues .

4.2. Cross-reactivity and ADE Risks

• Dengue Virus Antibodies: Some anti-DENV antibodies (e.g., E105, E106) exhibit serotype-specific neutralization but lack cross-reactivity . Modifications to the Fc region (e.g., LALA mutations) reduce Fc-mediated effector functions to mitigate antibody-dependent enhancement (ADE) .

• Influenza Antibodies: Broadly neutralizing antibodies like 1G01 target neuraminidase and inhibit multiple influenza subtypes via conserved epitopes .

Recommendations for "At1g50220 Antibody" Research

1. Verify Identifier: Confirm whether "At1g50220" refers to a gene, protein, or antibody with updated literature.

2. Explore Plant Antibodies: If targeting a plant protein, consult specialized databases (e.g., Arabidopsis Antibody Database) or recent proteomic studies.

3. Adopt Rigorous Validation: Use peptide microarrays , knockout models , and competitive binding assays to assess specificity.